Global trends and focuses of GLP-1RA in obesity: A bibliometric analysis and visualization from 2014 to 2024

Q2 Medicine

Obesity Medicine Pub Date : 2025-09-01 DOI:10.1016/j.obmed.2025.100640

Riad Mohammed Abdelrahman , Suleiman I. Sharif , Taha Hussein Musa , Hassan Hussein Musa , Ismail Adam Arbab , Mohsen Hussein Suleiman , Khalid Ahmed Mohammed , Sahar Ibrahim Gismallah , Chiamaka Linda Mgbechidinma , Mohammed Jalal , Eltieb Omer Ahmed

{"title":"Global trends and focuses of GLP-1RA in obesity: A bibliometric analysis and visualization from 2014 to 2024","authors":"Riad Mohammed Abdelrahman , Suleiman I. Sharif , Taha Hussein Musa , Hassan Hussein Musa , Ismail Adam Arbab , Mohsen Hussein Suleiman , Khalid Ahmed Mohammed , Sahar Ibrahim Gismallah , Chiamaka Linda Mgbechidinma , Mohammed Jalal , Eltieb Omer Ahmed","doi":"10.1016/j.obmed.2025.100640","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Obesity is a multifaceted disease with complex causes, distinct pathophysiology, numerous comorbidities, and significant health impacts. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become leading pharmacological options for its management. Our objective was to conduct a comprehensive analysis of the literature on GLP-1RAs in obesity within the Scopus database and identify relevant articles published between 2014 and 2024.</div></div><div><h3>Methods</h3><div>We perform a systematic bibliometric analysis to identify key trends, major sources, and emerging topics in GLP-1RA obesity research. The data were analyzed using VOS viewer (Var1.6.20) and the Biblioshiny tool.</div></div><div><h3>Results</h3><div>A total of 1702 documents were analyzed. Research output remained steady from 2014 to 2020 (approximately 50 documents per year), followed by exponential growth starting in 2020, peaking in 2024 (566 documents). The average number of citations per article peaked at 92 in 2018 before it dropped to 7 in 2024. Among the 130 contributing countries, the United States led with 25.9 % of publications. HOLST J.J. (University of Copenhagen) was the most prolific author (45 publications, 1901 citations, h-index 22). “<em>Diabetes, obesity and metabolism”</em> was the most active journal, publishing 105 articles. (h_index: 39, impact factor: 5.4 (2023)).</div><div>Keywords and thematic analyses revealed increasing research interest in specific agents (e.g., Semaglutide, Tirzepatide, and Dulaglutide) and in themes such as body weight loss, heart failure, cohort analysis, and long-term follow-up. Liraglutide and Semaglutide are the most studied. Keyword analysis did not highlight safety concerns related to cancer risk, as previously speculated.</div></div><div><h3>Conclusion</h3><div>This bibliometric analysis shows rapid growth in GLP-1RA obesity research, underscoring the need to expand focus beyond efficacy to long-term safety, real-world outcomes, and equitable access through international collaboration.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"57 ","pages":"Article 100640"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451847625000600","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Obesity is a multifaceted disease with complex causes, distinct pathophysiology, numerous comorbidities, and significant health impacts. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become leading pharmacological options for its management. Our objective was to conduct a comprehensive analysis of the literature on GLP-1RAs in obesity within the Scopus database and identify relevant articles published between 2014 and 2024.

Methods

We perform a systematic bibliometric analysis to identify key trends, major sources, and emerging topics in GLP-1RA obesity research. The data were analyzed using VOS viewer (Var1.6.20) and the Biblioshiny tool.

Results

A total of 1702 documents were analyzed. Research output remained steady from 2014 to 2020 (approximately 50 documents per year), followed by exponential growth starting in 2020, peaking in 2024 (566 documents). The average number of citations per article peaked at 92 in 2018 before it dropped to 7 in 2024. Among the 130 contributing countries, the United States led with 25.9 % of publications. HOLST J.J. (University of Copenhagen) was the most prolific author (45 publications, 1901 citations, h-index 22). “Diabetes, obesity and metabolism” was the most active journal, publishing 105 articles. (h_index: 39, impact factor: 5.4 (2023)).

Keywords and thematic analyses revealed increasing research interest in specific agents (e.g., Semaglutide, Tirzepatide, and Dulaglutide) and in themes such as body weight loss, heart failure, cohort analysis, and long-term follow-up. Liraglutide and Semaglutide are the most studied. Keyword analysis did not highlight safety concerns related to cancer risk, as previously speculated.

Conclusion

This bibliometric analysis shows rapid growth in GLP-1RA obesity research, underscoring the need to expand focus beyond efficacy to long-term safety, real-world outcomes, and equitable access through international collaboration.

查看原文本刊更多论文

肥胖症中GLP-1RA的全球趋势和焦点：2014年至2024年的文献计量分析和可视化

肥胖是一种病因复杂、病理生理独特、合并症众多、影响健康的多面性疾病。胰高血糖素样肽-1受体激动剂（GLP-1RAs）已成为其管理的主要药理选择。我们的目标是对Scopus数据库中关于肥胖中GLP-1RAs的文献进行全面分析，并确定2014年至2024年间发表的相关文章。方法我们进行了系统的文献计量分析，以确定GLP-1RA肥胖研究的关键趋势、主要来源和新兴主题。使用VOS viewer （Var1.6.20）和Biblioshiny工具对数据进行分析。结果共分析文献1702份。从2014年到2020年，研究产出保持稳定（每年约50篇论文），随后从2020年开始呈指数增长，2024年达到峰值（566篇论文）。2018年，每篇文章的平均引用次数达到了92次的峰值，2024年降至7次。在130个贡献国家中，美国以25.9%的出版物领先。HOLST J.J.（哥本哈根大学）是最多产的作者（45篇出版物，1901次引用，h指数22）。《糖尿病、肥胖和新陈代谢》是最活跃的期刊，发表了105篇文章。（h_index: 39，影响因子：5.4(2023)）。关键词和专题分析显示，对特定药物（如Semaglutide、tizepatide和Dulaglutide）以及体重减轻、心力衰竭、队列分析和长期随访等主题的研究兴趣日益增加。利拉鲁肽和西马鲁肽是研究最多的。关键词分析并没有像之前推测的那样强调与癌症风险相关的安全问题。这项文献计量学分析显示，GLP-1RA肥胖研究的快速增长，强调需要通过国际合作将重点从疗效扩展到长期安全性、现实结果和公平获取。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity Medicine Medicine-Public Health, Environmental and Occupational Health

CiteScore

5.50

自引率

0.00%

发文量

审稿时长

40 days

期刊介绍： The official journal of the Shanghai Diabetes Institute Obesity is a disease of increasing global prevalence with serious effects on both the individual and society. Obesity Medicine focusses on health and disease, relating to the very broad spectrum of research in and impacting on humans. It is an interdisciplinary journal that addresses mechanisms of disease, epidemiology and co-morbidities. Obesity Medicine encompasses medical, societal, socioeconomic as well as preventive aspects of obesity and is aimed at researchers, practitioners and educators alike.